ClinicalTrials.gg
TerminatedNCT04508842Updated Sep 28, 2022

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

A Phase 1 interventional study of CD19/CD22-Dual-STAR-T in Refractory and Relapsed B Cell Acute Leukemia, sponsored by Hebei Yanda Ludaopei Hospital. Terminated at 1 site in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Hebei Yanda Ludaopei Hospital · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Adjustment plan

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Study summary

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute leukemia .

Read the detailed description

Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.The purpose of current study is to evaluate the clinical safety and efficacy of CD19/CD22-Dual-STAR-T cells therapy in patients with refractory and relapsed B-ALL.Safety and efficacy of Dual-STAR-T cells therapy will be monitored. The primary endpoint is the safety of Dual-STAR-T cells including the effect ratio of CRS and ICANS, ORR. The secondary endpoint is the Dual-STAR-T cell proliferation ratio and Dual-STAR gene copied number in peripheral blood(PB), and progression free survival(PFS ), overall-survival(OS) and duration of overall response(DOR).

02

Conditions studied

  • Refractory and Relapsed B Cell Acute Leukemia
03

In context

Lead sponsor

Hebei Yanda Ludaopei Hospital is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 1 to 70 years.
  2. Prelapsed and refractorys B-ALL at least with one of the following conditions:

    • Could not achieve CR after 2course of chemotherapy.
    • Could not achieve CR or relapse after or multi-line salvage chemotherapy, or MRD≥0.1%.
    • Relapse within 12 months after first remission or MRD≥0.1%.
    • Relapse after achieved CR in hematopoietic stem cell transplantation (HSCT), or MRD≥0.1%.
    • For Ph + patients: Failure to tolerate TKI or TKI treatment failure could be enrolled.
  3. CD19 and/or CD22 positive within 3 months.
  4. 0-2.
  5. Estimated ≥ 3 months.
  6. Women of childbearing age must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective to ensure 12 months after discontinuation of treatment during the study period not pregnant inside.
  7. Patients who voluntarily sign and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion criteria

Exclusion Criteria:

  1. Active infections that are difficult to control
  2. and ,either of which is positive
  3. Central nervous system leukemias that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy
  4. Patients are receiving anti- treatment within 4 weeks of before screening.
  5. Performed major surgery within 4 weeks before screening.
  6. Patients have received chemotherapy within 7 days of screening.
  7. Experimental drugs were used within 4 weeks before screening.
  8. Received allogeneic cell therapy within 6 weeks prior to cell infusion.
  9. Patients have history of epilepsy or central nervous system diseases.
  10. Severe thyroid dysfunction
  11. Patients with active disease.
  12. Pregnant or lactating women.
  13. The patient does not agree to use effective during treatment and for the following 12 months;
  14. The researchers found that it was unsuitable for the recipients to be enrolled.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    CD19/CD22-Dual-STAR-T

    CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.

    Biological: CD19/CD22-Dual-STAR-T

Interventions

  • BiologicalCD19/CD22-Dual-STAR-T

    Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with adverse events.

    Percentage of participants with adverse events.

    Time frame: 12 months

Secondary outcomes

  1. Objective Remission Rate(ORR)

    The percentage of participants who achieved complete remission(CR) and CR in over all participants.

    Time frame: 12 months

  2. Proliferation ratio of Dual-STAR-T cells

    Time frame: 12 months

07

Study locations

1 site
  • Hebei Yanda Ludaopei Hospital
    Sanhe, Hebei 065200, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in May 2022, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2020
First posted
Aug 11, 2020
StartActual
Oct 10, 2020
Primary completionActual
May 1, 2022
CompletionActual
May 1, 2022
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04508842
Lead sponsor
Hebei Yanda Ludaopei Hospital
Collaborators
China Immunotech (Beijing) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Oct 10, 2020
Primary completion
May 1, 2022
Completion
May 1, 2022
Last update
Sep 28, 2022

Study contacts

Xian Zhang, PhD
study director · Hebei Yanda Ludaopei Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion